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Human immunodeficiency virus type 1 (HIV-1) is unique in that it encodes its own transcriptional activator Tat, which
specifically binds to the viral mRNA sequence TAR (transactivation response) element and activates viral transcription at the
step of elongation as well as initiation. We recently reported that fluoroquinoline derivatives inhibited HIV-1 replication most
likely by blocking viral transcription. In this report, we investigated the mechanism of action of one such compound
7-(3,4-dehydro-4-phenyl-1-piperidinyl)-1,4-dihydro-6-fluoro-1-methyl-8-trifluoromethyl-4-oxoquinoline-3-carboxylic acid (K-37). We
demonstrated that K-37 inhibited not only Tat but also other RNA-dependent transactivators. No effect was observed with
DNA-dependent transactivators such as p65 (NF-kB) and Gal4VP16. Moreover, K-37 did not inhibit carboxyl-terminal domain
(CTD)-kinase activities of CDK-activating kinase (CAK) and positive transcription elongation factor b (P-TEFb), which are
known to be involved in Tat-mediated transactivation at the step of transcriptional elongation. It is suggested that RNA-
mediated transactivation may involve a common unknown factor to which K-37 directly interacts. Since K-37 did not appear
to block DNA-mediated transactivation and thus did not show strong nonspecific cytotoxicity as reported previously, K-37 and
its derivative compounds are considered to be feasible candidates for a novel AIDS therapy. © 2000 Academic Press
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Tat is one of the regulatory proteins encoded by hu-
man immunodeficiency virus type 1 (HIV-1) and is essen-
tial for the virus replication. Tat is a 14-kDa protein
located predominantly in the nucleus of the virus-in-
fected cells and interacts with the transactivation re-
sponse (TAR) element, which is located immediately
downstream of the viral mRNA cap site (Sodroski et al.,
1985; Okamoto and Wong-Staal, 1986; Selby et al., 1989).
Despite the relatively small size of Tat protein, it strongly
stimulates the gene expression of HIV provirus in multi-
ple ways (reviewed in Okamoto, 1995; Jones, 1997; Jeang
et al., 1999; Kahn, 1999): First, the formation of Tat–TAR
complex was suggested to induce augmented transcrip-
tion from the DNA template containing the TAR element,
indicating that TAR might be the RNA equivalent of DNA
enhancer element (thus called “RNA enhancer”) (Sharp
and Marciniak, 1989). The involvement of Tat in transcrip-
tional initiation was supported by the fact that the fusion
protein containing the GAL4 DNA-binding region and the
Tat activation domain could support the transcriptional
activation (Southgate et al., 1990). In fact, Tat has been
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402shown to interact with RNA polymerase II holoenzyme
(Mavankal et al., 1996) and histone acetylase (Hottiger
and Nabel, 1998). Second, Tat was shown to participate
in TAR-specific elongation complex formation and induce
the cotranscriptional modification of the initiated tran-
scription complex to a more processive form (Laspia et
al., 1989; Marciniak and Sharp, 1991; Parada and Roeder,
1996; Okamoto et al., 1996). In addition, recent studies
showed that Tat increased the rate of transcriptional
elongation by inducing hyperphosphorylation of the car-
boxyl terminal domain (CTD) of RNA polymerase II (Her-
mann and Rice, 1995; Cujec et al., 1997; Garcia-Martinez
et al., 1997; Gold et al., 1998; Mancebo et al., 1997;
ujinaga et al., 1998). This induction by Tat is considered
hrough the recruitment of the CTD kinases, such as
yclin-dependent kinase (CDK)-activating kinase (CAK)
nd positive transcription elongation factor b (P-TEFb), to
he vicinity of active transcription. Moreover, one of the
omponents of P-TEFb, cyclin T1, has been identified as
Tat cofactor for its binding to TAR (Wei et al., 1998).
hus, the cumulative effects of Tat actions on HIV gene
xpression will render this small protein with exception-
lly high potency as a transcriptional activator. Because
f its role in HIV-1 replication, Tat has long been re-
arded as a feasible target for anti-HIV therapy.
We have previously reported that fluoroquinoline de-
ivatives have a potent anti-HIV-1 activity and inhibit the
iral replication in acutely infected cells as well as chron-
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403INHIBITION OF TAT-MEDIATED TRANSACTIVATION BY K-37ically infected cells (Baba et al., 1997, 1998; Okamoto et
l., 1999). Our preliminary experiment using transient
AT assay in HeLa cells suggested that one such
ompound, 7-(3,4-dehydro-4-phenyl-1-piperidinyl)-1,4-di-
ydro-6-fluoro-1-methyl-8-trifluoromethyl-4-oxoquinoline-
-carboxylic acid (K-37), could inhibit Tat-mediated HIV
ransactivation (Baba et al., 1998). Unlike other com-
ounds previously reported as putative Tat inhibitors,
-37 showed remarkably low cytotoxicity and wide ther-
peutic window. In this study, we further analyzed the
ode of action of K-37 and found that it inhibited RNA-
ediated transactivation without inhibiting the CTD ki-
ase activities of CAK and P-TEFb. Interestingly, other
eterologous RNA-mediated transactivation systems, us-
ng Rev-based effectors on the reporter construct con-
aining the Rev-responsive element (RRE), were similarly
nhibited by K-37. The DNA-mediated transactivation by
65 (NF-kB) or Gal4VP16, on the other hand, was not
ffected. These data suggest that K-37 is a new type of
ranscription inhibitor that specifically blocks RNA-medi-
ted transactivation including Tat. It is also suggested
hat there may be a common mechanism to which K-37
nteracts.
RESULTS
-37 inhibited HIV-1 replication in acutely and
hronically infected cells
To confirm the previously reported effects of K-37 on
IV-1 replication, we applied both acute HIV-1 infection
n CEM and U937 cells and chronic latent infection in
CH-2 and U1 cells, which were not examined in our
revious report (Baba et al., 1998). CEM cells and U937
cells (1 3 105 cells/ml) were infected with HIV-1IIIB in the
presence of various concentrations of K-37. Four days
after viral infection, the supernatant was collected and
determined for the viral p24 level. As shown in Fig. 1,
K-37 inhibited HIV-1 replication in dose-dependent man-
ner with the 50% effective concentration value (EC50) of
0.15 and 0.018 mM in CEM and U937 cells, respectively.
he 50% cytotoxicity value (IC50) of K-37 in CEM and U937
ells, as determined by MTT assay, was 2.1 and 0.85 mM,
respectively. There was no significant cytotoxicity for
HeLa cells #5 mM (the cell viability was 94% at 5 mM).
This wide variation of K-37 cytotoxicity appeared to de-
pend on the cell proliferation rate as the major side effect
of K-37 was cytostatic effect rather than cytocidal one
(our unpublished results). To test the effect of K-37 on
chronic latent infection, ACH-2 cells and U1 cells were
incubated in the presence of various concentrations of
K-37 for 2 h, stimulated with 10 ng/ml TNF-a, and further
incubated. The culture supernatants were collected after
3 days of stimulation and their p24 antigen levels were
determined. As shown in Fig. 1, K-37 inhibited HIV-1
replication in these cells with EC50 values of 0.082 mM
ACH-2) and 0.013 mM (U1). The IC50 value was 2.7 mMACH-2) and 0.62 mM (U1). Thus, the selectivity index
IC50/EC50) was 14, 47, 33, and 48 for CEM (acute infec-
tion), U937 (acute infection), ACH-2 (chronic infection
with TNF-a stimulation), and U1 (chronic infection with
TNF-a stimulation) cells, respectively.
K-37 inhibits Tat-activated transcription
from HIV-1 LTR
We then examined the effect of K-37 on Tat-mediated
transactivation from HIV-1 LTR using transient CAT assay
with wild-type and mutant (transactivation-defective) Tat.
In Fig. 2, HeLa cells were transfected with a reporter
plasmid expressing CAT under the control of HIV-1 LTR
(pHIVSCAT) and an effector plasmid expressing Tat (pS-
VHATAT) or its control (pSVTATZX) (Okamoto et al., 1996).
After transfection, the cells were incubated with various
concentrations of K-37 for 48 h and determined for the
CAT enzyme activity. As presented in Fig. 2A, K-37 inhib-
FIG. 1. K-37 inhibited HIV-1 replication in acutely and chronically
infected cells. CEM cells and U937 cells were infected with HIV-1IIIB and
ultured in the presence of various concentrations of K-37. After a 4-day
ncubation, p24 antigen levels of culture supernatants were deter-
ined. ACH-2 cells and U1 cells were cultured in the presence of K-37
or 2 h, stimulated with 10 ng/ml TNF-a, and further incubated. After a
3-day incubation, the supernatant was collected and the p24 antigen
level was determined. The viable cell number was determined by the
MTT method. Data are expressed as the percent of control (no com-
pound). All experiments were carried out in triplicate and the mean and
SD values are shown.ited Tat-mediated transactivation from HIV-1 LTR in a
dose-dependent manner, whereas no significant effect
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404 OKAMOTO ET AL.was observed on the basal transcriptional level (when
nonfunctional Tat was expressed by pSVTATZX). In Fig.
2B, we confirmed that the same amount of Tat protein
was synthesized in each transfection by Western blot
analysis using anti-hemagglutinin antibody 12CA5 de-
tecting the epitope of the transduced Tat protein.
K-37 does not inhibit Tat-associated CTD kinases
Since a number of reports have indicated that CTD
kinases, CAK and P-TEFb, are involved in the Tat-medi-
ated transactivation, we examined whether K-37 could
inhibit CAK and P-TEFb kinase activity. In Fig. 3, each in
vitro kinase reaction for CAK (containing CDK7, Cyclin H,
and MAT1) and P-TEFb (containing CDK9 and Cyclin T)
and GST–CTD as a substrate was performed with vari-
ous concentrations of K-37. Although CTD phosphoryla-
tion either by CAK or P-TEFb was clearly demonstrated
as reported (Fisher et al., 1995; Cujec et al., 1997), K-37
FIG. 2. K-37 inhibits Tat-mediated transactivation from HIV-1 LTR. (A)
HeLa cells were transfected with lipofectamine using 1 mg reporter
(pHIVSCAT) and 1 mg effector (pSVHATAT or pSVTATZX) plasmid DNA
nd incubated in the presence of the indicated concentrations of K-37
or 48 h. These cells were harvested, and quantitative CAT assays were
one as described under Materials and Methods. Experiments were
erformed in triplicates and the mean and SD values are indicated. (B)
estern blot detection for Tat protein. The same protein samples as (A)
20 mg) were analyzed by Western blot with a-hemagglutinin antibody
12CA5 after SDS–15% polyacrylamide gel electrophoresis and electro-
blotting onto Hybond-N membranes. The arrow indicates the position
of HA-tagged Tat protein. The cell viability of HeLa cell culture at 5 mM
as 94% by MTT assay.did not show any significant inhibition even at the high-
est concentration (130 mM).Differential effects of K-37 on RNA- and
DNA-mediated transactivation
We then investigated the effect of K-37 on gene ex-
pression in other transactivation systems. Although Tat is
known to activate HIV-1 transcription by binding to TAR,
other heterologous systems could also support the RNA-
mediated transactivation. The effects of Rev–Tat (in
which Tat was fused to the RRE-binding domain of Rev)
(Fujinaga et al., 1998), Rev-VP16 (Ghosh. et al., 1996), and
ev-CDK9 (Wei et al., 1998) on the transactivation from
the reporter construct containing RRE are such exam-
ples. We thus adopted these systems to examine the
effect of K-37. As demonstrated in Fig. 4A, Rev–Tat fusion
protein (expressed by pSVRevTat effector plasmid) trans-
activated the gene expression from a reporter plasmid
pRRE-CAT through the interaction of RRE with Rev (RNA-
binding domain) by 152-fold as reported (Fujinaga et al.,
1998). When the transfected cells were treated with K-37,
the extent of transactivation was greatly inhibited in a
dose-dependent manner for the K-37 concentration. In
contrast, the DNA-mediated transactivation from
pG5CAT (containing five tandem repeats of the GAL4
binding site) by Gal4-Tat fusion protein in which the
DNA-binding domain of Gal4 was fused to Tat (ex-
pressed by pGal4Tat) was not affected by this com-
pound. Even some activation by K-37 of the transactiva-
tion of Gal4–Tat was noted. Basal transcription from
FIG. 3. K-37 does not inhibit Tat-associated CTD-kinases (CAK and
P-TEFb) in vitro. Kinase assays were done with the substrate GST-CTD
in the presence or the absence of K-37. The GST–CTD fusion protein (16
repeats of YSPTSPS) was over-expressed in Escherichia coli and pu-
rified on glutathione–Sepharose beads. The recombinant CAK trimer
complex was purified from Sf9 insect cells coinfected with baculovi-
ruses encoding human CDK7, MAT1, and cyclinH. The P-TEFb complex
was immunoprecipitated by anti-HA monoclonal antibody 12CA5 from
nuclear extracts derived from 293 cells stably expressing the HA-
tagged wild-type CDK9 and purified with protein-A–Sepharose column.
Each kinase reaction contained recombinant CAK (50 ng) or the P-TEFb
immunoprecipitated from 1 mg of nuclear extract (10-ml beads) and 25
mg of GST–CTD fusion protein (2.5-ml beads). Following incubation at
30°C for 1 h, the beads were washed twice in PBS before loading onto
SDS–PAGE (5–20% gradient). After drying the gels, the phosphorylated
GST–CTD proteins were visualized by autoradiography. The arrow
indicates the position of GST–CTD fusion protein.
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405INHIBITION OF TAT-MEDIATED TRANSACTIVATION BY K-37pRRE-CAT alone was not inhibited by K-37 (data not
shown) as observed with pHIVSCAT (Fig. 2A).
We further examined the effects of K-37 on other DNA-
mediated transactivation systems. In Fig. 4B, the effects
of K-37 on the transactivation by Gal4-VP16 fusion protein
(expressed by pGal4VP16) or by p65 (RelA) (expressed
by pCMVp65) were examined. These DNA-dependent
transactivators stimulated transcription from their own
reporter plasmids, pG5CAT and p4xkB-Luc (a luciferase
eporter plasmid containing four tandem repeats of kB
ites), by 79- and 11-fold, respectively. However, there
FIG. 4. Differential inhibition of RNA- and DNA-mediated transacti-
ation by K-37. After transfection, the cells were incubated in the
bsence or presence of the indicated concentrations of K-37 for 48 h
nd CAT or luciferase assays were carried out. (A) HeLa cells were
ransfected with 1 mg reporter plasmid DNA (pRRE-CAT or pG5-CAT)
nd 1 mg effector plasmid (pSVRevTat or pSVGAL4Tat). (B) HeLa cells
ere transfected with lipofectamine using 1 mg reporter plasmid (pG5-
CAT or 4xkB-Luc) and 1 mg effector plasmid [pSVGAL4VP16 or
65(relA)]. (C) HeLa cells were transfected with 1 mg reporter (pRRE-
AT) and 1 mg effector (pSVRevVP16or pSVRevCDK9) plasmid DNA.as no significant effect by K-37.
Finally, we examined the effect of K-37 on other het-
a
trologous RNA-dependent transactivation systems de-
oid of any part of Tat protein (Wei et al., 1998). As shown
in Fig. 4C, Rev-VP16 (expressed by pSVRevVP16) and
Rev-CDK9 (expressed by pSVRevCDK9) fusion proteins
transactivated the RRE (RNA)-mediated CAT gene ex-
pression by 38- and 25-fold, respectively, in HeLa cells
as reported (Wei et al., 1998). When the transfected cells
were treated with K-37, the extents of transactivation
were inhibited as shown in Fig. 4C. There was no de-
tectable cytotoxicity of K-37 on HeLa cells under these
concentrations (data not shown). These findings indicate
that K-37 could inhibit only the RNA-mediated transacti-
vation as far as we examined.
DISCUSSION
Transcription is an essential step for the viral life cycle
of HIV-1 and is the only step for the amplification of the
viral genetic information. Because Tat activates viral tran-
scription at multiple steps, the net extent of Tat-mediated
transactivation is one of the greatest among various
transcriptional activators. Thus, Tat has been considered
to play a major role in HIV replication and, therefore, a
feasible target for anti-HIV therapy. However, initial at-
tempts to find Tat-inhibitors were hampered because
of the high cytotoxicity of potential compounds such
as 5,6-dichloro-1-b-D-ribofuranosyl-benzimidazole (DRB)
Braddock et al., 1991) and 7-chloro-5-(2-pyrryl)-3-H-1,4-
enzodiazepine-2(H)-one (Ro 5–3335) (Hsu et al., 1991).
he identification of the CTD activity, particularly P-TEFb,
s a pharmacological target of DRB (Marciniak and
harp, 1991; Marshall et al., 1996) has prompted the
nderstanding of Tat action on transcription elongation. It
as shown that Tat-mediated transactivation requires
he CTD of RNA polymerase II (Herrmann and Rice, 1995;
kamoto et al., 1996; Mancebo et al., 1997). Moreover,
at was shown to associate with CTD kinases, CAK of
FIIH and P-TEFb, and these interactions were essential
or the Tat action on elongation of the viral transcripts
Cujec et al., 1997; Parada and Roeder, 1996; Garcia-
artinez et al., 1997; Zhu et al., 1997). Cyclin T1, as a
omponent of P-TEFb together with CDK9, was subse-
uently identified as a cellular co-factor of Tat for its
nteraction with TAR (Wei et al., 1998).
In our previous reports (Baba et al., 1998; Okamoto et
al., 1999), we demonstrated that fluoroquinoline deriva-
tives could inhibit HIV-1 replication at high selectivity,
although the mechanism of action was not known.
Among these fluoroquinoline derivatives, K-37 and K-12
showed the highest selectivity (Baba et al., 1998). We
also demonstrated the synergy of one of such compound
K-12 with other anti-retroviral agents such as zidovudine,
lamivudine, and nelfinavir (Okamoto et al., 1999). In this
tudy, we found that K-37 inhibited RNA-dependent trans-
ctivation including Tat but not DNA-dependent transac-
ivation. Interestingly, K-37 inhibited Tat transactivation
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406 OKAMOTO ET AL.without affecting the cellular CTD kinases, CAK and P-TEFb,
unlike DRB (Marshall et al., 1996; Mancebo et al., 1997).
The fact that K-37 could inhibit only the RNA-mediated
transactivation without blocking CTD kinases indicates
that RNA-mediated transactivation might involve addi-
tional mechanism to which K-37 interacts. Although the
mechanism of RNA-mediated transactivation is yet to be
elucidated, it is possible that K-37 may interact with, for
example, factors involved in transcriptional elongation
such as elongin (Aso et al., 1995), DSIF (Wada et al.,
998), and NELF (Yamaguchi et al., 1999). Use of K-37 as
chemical probe should be effective in search of a
ritical molecule for Tat-mediated transactivation.
In conclusion, fluoroquinoline derivatives such as K-37
ave a potential efficacy as a novel anti-HIV compound.
owever, the target molecule and in vivo toxicity as well
as efficacy should be explored before they are recog-
nized as promising candidates for the treatment of HIV
infection in humans.
MATERIALS AND METHODS
Cell culture and transfection. The human T cell lines
(CEM and ACH-2) and monocyte cell lines (U937 and U1)
were maintained in RPMI 1640 medium supplemented
with 10%(vol/vol) heat-inactivated fetal calf serum, 100
units/ml penicillin G, and 100 mg/ml streptomycin as
described (Baba et al., 1997, 1998). HeLa cells were
maintained in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% (vol/vol) heat-inactivated fetal calf
serum, penicillin, and streptomycin. The cytotoxicity of
K-37 was analyzed by measuring the number of viable
cell using the 3-(4,5-demethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay (Baba et al., 1998;
Okamoto et al., 1999).
Plasmids used in this study include: pHIVSCAT (Oka-
moto et al., 1996), pRRECAT (Fujinaga et al., 1998),
p4xkB-Luc (Yang et al., 1999), pSVHTAT and pSVTATZX
Okamoto et al., 1996), pSVRevTat (Fujinaga et al., 1998),
pSVRevVP16 and pSVRevCDK9 (Wei et al., 1998),
pG5CAT, pGal4VP16, and pGal4Tat (Ghosh et al., 1996),
and pCMVp65 [expressing the p65 (RelA) subunit of
nuclear factor kB (NF-kB)] (Yang et al., 1999). HeLa
ells were transfected with 1 mg of reporter plas-
id (pHIVSCAT, pRRECAT, pG5CAT, or p4xkB-Luc) to-
gether with 1 mg of effector plasmid DNA (pSVHATAT,
pSVTATZX, pSVRevTat, pSVRevVP16, pSVRevCDK9,
pGal4VP16, pGal4Tat, or pCMVp65) with lipofectamine
(Gibco BRL, Gaithersburg, MD) as described previously
(Okamoto et al., 1996; Cujec et al., 1997; Fujinaga et al.,
1998; Yang et al., 1999). After transfection, the cells were
incubated with various concentrations of the compound
for 48 h.
CAT and luciferase assays. Transfected cells were
harvested, and quantitative chloramphenicol acetyltrans-
ferase (CAT) enzymatic assays were done as described(Neuman et al., 1987; Selby et al., 1989; Okamoto et al.,
1996; Cujec et al., 1997). Briefly, 48 h after the transfection
using lipofectamine, cells were lysed in a buffer contain-
ing 250 mM Tris–HCl (pH 7.5) and 0.1% Triton X-100 and
sonicated, and the lysate was clarified by centrifugation
at 12,000 g for 15 min. CAT activities were measured by
a liquid scintillation assay using [3H]acetyl CoA (8.1Gbq/
mol; ICN Radiochemicals) (Neuman et al., 1987). As an
nternal control, 0.2 mg of pCMVGal was cotransfected
with CAT reporter plasmid. Results of transient CAT gene
expression assays were normalized for transfection effi-
ciency by b-galactosidase activity (Hayashi et al., 1993;
ujinaga et al., 1998). Experiments were performed in
riplicates and the results were represented by the mean
alue and the standard deviation. To confirm the results,
ach experiment was carried out at least two times.
Transient luciferase assays were performed as de-
cribed (Yang et al., 1999). Transfections of HeLa cells
ith 4xkB-Luc and/or pCMVp65 were similarly carried
out as in CAT assays. As an internal control, pRL-TK,
expressing Renilla luciferase under the control of TK
romoter of herpes simplex virus, was cotransfected and
he luciferase activity was normalized by the Renilla
uciferase activity.
Antiviral assays. Acute HIV-1 infection was carried out
ith CEM and U937 cells as described (Baba et al., 1997,
998; Okamoto et al., 1999). These cells (1 3 105 cells/ml)
ere infected with HIV-1IIIB (at a m.o.i. of 0.1). After viral
bsorption for 2 h, the cells were extensively washed to
emove unadsorbed virus particles and cultured in the
resence of various concentrations of K-37. After a 4-day
ncubation at 37°C, the culture supernatants were col-
ected and their p24 antigen levels were determined with
sandwich ELISA kit (Cellular Products, Buffalo, NY)
ccording to the manufacturer’s protocol.
The effect of the compound against chronic HIV-1
nfection was based on the inhibition of p24 antigen
roduction in the supernatant of ACH-2 or U1 cells as
escribed (Baba et al., 1998; Okamoto et al., 1999).
Briefly, ;1 3 105 cells/ml of ACH-2 cells or U1 cells were
incubated in the presence of various concentrations of
K-37 for 2 h, stimulated with 10 ng/ml tumor necrosis
factor a (TNF-a) (Genzyme, Cambridge, MA), and further
incubated. After a 3-day incubation at 37°C, the culture
supernatants were collected and determined for their
p24 antigen levels.
In vitro kinase assay. Production and purification of
these CTD kinases, CAK and P-TEFb, were performed as
previously reported (Fisher et al., 1995; Cujec et al.,
997). Briefly, recombinant CAK trimer, a kind gift from Dr.
. O. Morgan, was purified from Sf9 insect cells coin-
ected with baculoviruses expressing human CDK7,
AT1, and cyclinH as described (Cujec et al., 1997;
isher et al., 1995). The P-TEFb complex was immuno-
precipitated from nuclear extracts derived from 293 cells
stably expressing HA-tagged wild-type CDK9 (Cujec et
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407INHIBITION OF TAT-MEDIATED TRANSACTIVATION BY K-37al., 1997; Zhu et al., 1997). The HA-bound immunoprecipi-
ate bound to the protein-A–Sepharose beads was used
s the PTEF-b complex after washing three times in
inding buffer [50 mM HEPES (pH 7.6), 250 mM NaCl,
mM EDTA, 0.1% Triton X-100, 5 mM DTT, 0.2 mM PMSF,
mM sodium metabisulfite] and two times in the CTD-
inase buffer [20 mM Tris–HCl (pH 7.6), 50 mM KCl, 5 mM
gCl2, 2.5 mM MnCl2, 10 mM DTT]. The GST–CTD fusion
rotein containing 16 copies of the heptapeptide repeat
equence YSPTSPS expressed in Escherichia coli (a
ind gift from Dr. J. L. Corden) was purified by affinity
hromatography using glutathione–Sepharose beads
Amersham Pharmacia Biotech, Piscataway, NJ) as de-
cribed (Patturajan et al., 1997).
Each kinase reaction containing recombinant CAK (50
g) or P-TEFb immunoprecipitated from 1 mg of nuclear
xtract (10 ml volume of beads) and ;25 mg of GST-CTD
fusion protein (2.5 ml beads) was performed with various
concentrations of K-37 up to 130 mM. Reactions were
upplemented with 10 mCi of (1 Ci 5 37 Gbq) g-[32P]ATP
nd 50 mM of unlabeled ATP in a final reaction volume of
50 ml. Following incubation at 30°C for 1 h, the beads
ere washed twice in PBS before loading onto SDS–
AGE (5–20% gradient). After drying, the phosphorylated
TD substrate was visualized by autoradiography.
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